Sulzer Medica Launches Innex(TM) Knee Systems

New Knee System Provides Greater Flexibility to Orthopedic Surgeons



Apr 03, 2001, 01:00 ET from Sulzer Medica Management AG

    WINTHERTHUR, Switzerland, April 3 /PRNewswire/ -- Sulzer Medica (NYSE:   SM)
 starts to launch the knee prostheses Innex(TM) in Europe.  The innovative knee
 system has been developed in close cooperation with leading Swiss and Austrian
 orthopedic surgeons.  Innex provides to surgeons the opportunity to address
 the multitude of different indications in total knee endoprostheses with only
 one system, reducing the complexity of the surgery while expanding the
 opportunities to act exactly on the requirements of each patient.
     Innex is currently launched in the major European markets.  The worldwide
 (without USA) launch will follow in early 2002.  Innex has CE Mark approval
 since late 1999.  In Europe approximately 230 000 knee prosthesis are
 implanted annually at an annual growth rate of 6-7%.  Sulzer Medica aims to
 grow significantly above the market average.
     Generally, knee prostheses are distinguished if they are fixated in the
 tibial or femoral bone with or without bone cement, or if they are implanted
 with an artificial meniscus that is either fix or mobile.  Which system is
 ultimately selected depends upon the age of the patient, the type of joint
 disease at hand, the stability of his ligaments, etc.
     The Innex knee system has been developed by combining the experience of
 orthopedic surgeons with innovative technological solutions.  Thus,
 technologies have been incorporated in the development of the knee system that
 improve the articulation of the prosthesis as well as its fixation in the
 bone.  As a result, Innex covers all indications in total knee endoprostheses
 with just one system reducing the surgical technique deployed as well as the
 instrumentation required for implantation.  This also reduces logistics in the
 hospitals and limits the need for training of the personnel.  Additionally,
 Innex is implanted with an innovative surgical instrumentation that enables a
 precise preparation of the tibial and femoral bone for the fixation of the
 prosthesis.
     Innex has been developed in close cooperation with the Swiss Orthopedics
 surgeons Dr. med. Urs Munzinger and Dr. med. Tomas Drobny from the Clinic
 Wilhelm Schulthess in Zurich as well as with the Austrian orthopedic surgeons
 Prof. Dr. med. Wolfgang Schwaegerl and Prof. Dr. med. Nikolaus Boehler.  Since
 its first implantation in 1996 Innex has been implanted as part of a
 multicenter clinical study for more than 2000 times in 90 European clinics.
 The results of this study have been presented to more than 300 experts and
 orthopedics surgeons from Europe and overseas from March 30 to 31 in a product
 launch meeting in Crans Montana, Switzerland.
     "We have obtained excellent results with Innex," said Dr. med. Urs
 Munziger and Dr. med. Tomas Drobny of the Clinic Wilhelm Schulthess in Zurich.
 "Innex simplifies not only the surgery, it also enhances the flexibility, is
 implanted with greater precision and may thus shorten the duration of the
 rehabilitation for the patient, who may faster regain his natural freedom of
 movement."
     Headquartered in Winterthur, Switzerland, Sulzer Medica develops,
 manufactures and markets implantable medical devices and biological products
 for cardiovascular and orthopedic markets worldwide.  The Company's product
 offering includes joint prostheses, spinal implants, dental implants, trauma
 surgery products, heart valves, and vascular grafts (Swiss Stock Exchange:
 SMEN; NYSE:   SM).
 
     THE SAFE HARBOR STATEMENTS UNDER THE U.S. PRIVATE SECURITIES LITIGATION
      REFORM ACT 1995
     This report contains forward-looking statements including, but not limited
 to, projections of future performance of materials and products, financial
 conditions, results of operations and cash flows, containing risks and
 uncertainties.  These statements are subject to change based on known risks
 detailed from time to time in the Company's Securities and Exchange Commission
 filings and other known and unknown risks and various other factors, which
 could cause the actual results or performance to differ materially from the
 statements made herein.
 
     For more information, please contact:
     Henner Alms, phone +41 52 262 71 50, fax +41 52 262 00 59
     E-mail: press-relations@sulzermedica.com
 
     For Investor Relations:
     Josef Rueegg, phone +41 52 262 53 43, fax +41 52 262 00 59
     E-mail: josef.rueegg@sulzer.com
 
     For Investor Relations in the US:
     Jim Johnson, phone +1 713 561 63 76, fax +1 713 561 63 80
     E-mail: jim.johnson@smedica.com
 
 
     The press release is available on internet:
 www.sulzermedica.com/media/mainpage.htm
 
 

SOURCE Sulzer Medica Management AG
    WINTHERTHUR, Switzerland, April 3 /PRNewswire/ -- Sulzer Medica (NYSE:   SM)
 starts to launch the knee prostheses Innex(TM) in Europe.  The innovative knee
 system has been developed in close cooperation with leading Swiss and Austrian
 orthopedic surgeons.  Innex provides to surgeons the opportunity to address
 the multitude of different indications in total knee endoprostheses with only
 one system, reducing the complexity of the surgery while expanding the
 opportunities to act exactly on the requirements of each patient.
     Innex is currently launched in the major European markets.  The worldwide
 (without USA) launch will follow in early 2002.  Innex has CE Mark approval
 since late 1999.  In Europe approximately 230 000 knee prosthesis are
 implanted annually at an annual growth rate of 6-7%.  Sulzer Medica aims to
 grow significantly above the market average.
     Generally, knee prostheses are distinguished if they are fixated in the
 tibial or femoral bone with or without bone cement, or if they are implanted
 with an artificial meniscus that is either fix or mobile.  Which system is
 ultimately selected depends upon the age of the patient, the type of joint
 disease at hand, the stability of his ligaments, etc.
     The Innex knee system has been developed by combining the experience of
 orthopedic surgeons with innovative technological solutions.  Thus,
 technologies have been incorporated in the development of the knee system that
 improve the articulation of the prosthesis as well as its fixation in the
 bone.  As a result, Innex covers all indications in total knee endoprostheses
 with just one system reducing the surgical technique deployed as well as the
 instrumentation required for implantation.  This also reduces logistics in the
 hospitals and limits the need for training of the personnel.  Additionally,
 Innex is implanted with an innovative surgical instrumentation that enables a
 precise preparation of the tibial and femoral bone for the fixation of the
 prosthesis.
     Innex has been developed in close cooperation with the Swiss Orthopedics
 surgeons Dr. med. Urs Munzinger and Dr. med. Tomas Drobny from the Clinic
 Wilhelm Schulthess in Zurich as well as with the Austrian orthopedic surgeons
 Prof. Dr. med. Wolfgang Schwaegerl and Prof. Dr. med. Nikolaus Boehler.  Since
 its first implantation in 1996 Innex has been implanted as part of a
 multicenter clinical study for more than 2000 times in 90 European clinics.
 The results of this study have been presented to more than 300 experts and
 orthopedics surgeons from Europe and overseas from March 30 to 31 in a product
 launch meeting in Crans Montana, Switzerland.
     "We have obtained excellent results with Innex," said Dr. med. Urs
 Munziger and Dr. med. Tomas Drobny of the Clinic Wilhelm Schulthess in Zurich.
 "Innex simplifies not only the surgery, it also enhances the flexibility, is
 implanted with greater precision and may thus shorten the duration of the
 rehabilitation for the patient, who may faster regain his natural freedom of
 movement."
     Headquartered in Winterthur, Switzerland, Sulzer Medica develops,
 manufactures and markets implantable medical devices and biological products
 for cardiovascular and orthopedic markets worldwide.  The Company's product
 offering includes joint prostheses, spinal implants, dental implants, trauma
 surgery products, heart valves, and vascular grafts (Swiss Stock Exchange:
 SMEN; NYSE:   SM).
 
     THE SAFE HARBOR STATEMENTS UNDER THE U.S. PRIVATE SECURITIES LITIGATION
      REFORM ACT 1995
     This report contains forward-looking statements including, but not limited
 to, projections of future performance of materials and products, financial
 conditions, results of operations and cash flows, containing risks and
 uncertainties.  These statements are subject to change based on known risks
 detailed from time to time in the Company's Securities and Exchange Commission
 filings and other known and unknown risks and various other factors, which
 could cause the actual results or performance to differ materially from the
 statements made herein.
 
     For more information, please contact:
     Henner Alms, phone +41 52 262 71 50, fax +41 52 262 00 59
     E-mail: press-relations@sulzermedica.com
 
     For Investor Relations:
     Josef Rueegg, phone +41 52 262 53 43, fax +41 52 262 00 59
     E-mail: josef.rueegg@sulzer.com
 
     For Investor Relations in the US:
     Jim Johnson, phone +1 713 561 63 76, fax +1 713 561 63 80
     E-mail: jim.johnson@smedica.com
 
 
     The press release is available on internet:
 www.sulzermedica.com/media/mainpage.htm
 
 SOURCE  Sulzer Medica Management AG